Mehta Vimal's Form 4 filing
BioXcel Therapeutics, Inc. (BTAIQ) · filed Dec 17, 2024
- Accession no.
- 0001104659-24-129462
- Filed
- Dec 17, 2024, 6:08 PM ET
- Trade date
- Dec 14-16, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.13K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mehta VimalCIK 0001733369 | Director, Officer (CEO and President), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 14, 2024 | Common Stock | MOption exerciseAcquired | +2,610 | – | – | 58,403 | Direct | |
| Dec 15, 2024 | Common Stock | MOption exerciseAcquired | +3,500 | – | – | 61,903 | Direct | |
| Dec 16, 2024 | Common Stock | SSaleDisposed | −983 | $0.3641 | −$357.91 | 60,920 | Direct | |
| Dec 16, 2024 | Common Stock | SSaleDisposed | −2,134 | $0.3624 | −$773.36 | 59,605 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 14, 2024 | Common Stock | MOption exerciseDisposed | −2,610 | $0.00 | $0 | 13,049 | Direct | |
| Dec 15, 2024 | Common Stock | MOption exerciseDisposed | −3,500 | $0.00 | $0 | 31,500 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.